(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Fastly, Illumina, and Tattooed Chef.

The three biggest losers today are Sorrento Therapeutics, Fidelity National Information Services, and Blink Charging Co..

Winners today

1. Fastly (FSLY) – 28.12%

Fastly, Inc. operates an edge cloud platform for processing, serving, and securing its customer's applications in the United States, the Asia Pacific, Europe, and internationally. The edge cloud is a category of Infrastructure as a Service that enables developers to build, secure, and deliver digital experiences at the edge of the internet. It is a programmable platform designed for web and application delivery. The company offers Compute@Edge; developer hub that includes solution library patterns and recipes, API and language references, change logs, and Fastly Fiddle solutions; device detection and geolocation, edge dictionaries, edge access control lists, and edge authentication services; full site delivery services, such as dynamic site acceleration, origin shield, instant purge, surrogate keys, real-time logging and stats, cloud optimizer, programmatic control, edge databases, content compression, reliability, and modern protocols and performance services; and streaming solutions and services, including live streaming, media shield, and origin connect. It also provides edge security solutions, such as DDoS protection and cloud, edge web application firewall (WAF), transport layer security (TLS), platform TLS, and compliance services; unified web application and API protection solutions that includes runtime self-application protection, advanced rate limiting, API and ATO protection, account takeover protection, bot protection, and next generation WAF. In addition, the company offers edge applications, such as load balancers and image optimizers; video on demand; and managed edge delivery services. It serves customers operating in digital publishing, media and entertainment, technology, online retail, travel and hospitality, and financial services industries. The company was formerly known as SkyCache, Inc. and changed its name to Fastly, Inc. in May 2012. Fastly, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.

NYSE ended the session with Fastly rising 28.12% to $12.65 on Monday, after five consecutive sessions in a row of losses. NYSE rose 0.77% to $16,032.43, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Fastly has a trailing twelve months EPS of $-0.93.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.46%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 13.3% and a negative 27.3%, respectively.

More news about Fastly.

2. Illumina (ILMN) – 8.77%

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

NASDAQ ended the session with Illumina jumping 8.77% to $213.82 on Monday, following the last session’s upward trend. NASDAQ rose 1.48% to $11,891.79, after three successive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Illumina has a trailing twelve months EPS of $4.28.

PE Ratio

Illumina has a trailing twelve months price to earnings ratio of 49.96. Meaning, the purchaser of the share is investing $49.96 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.26%.

Sales Growth

Illumina’s sales growth is 0.3% for the present quarter and 0.7% for the next.

Yearly Top and Bottom Value

Illumina’s stock is valued at $213.82 at 16:32 EST, way under its 52-week high of $371.16 and way above its 52-week low of $173.45.

More news about Illumina.

3. Tattooed Chef (TTCF) – 7.66%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, and plant-based burgers. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores. As of December 31, 2021, it operated approximately 14,000 retail outlets. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef jumping 7.66% to $1.34 on Monday while NASDAQ jumped 1.48% to $11,891.79.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-0.069.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.9%.

More news about Tattooed Chef.

4. Zai Lab (ZLAB) – 6.76%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab jumping 6.76% to $40.41 on Monday, following the last session’s downward trend. NASDAQ jumped 1.48% to $11,891.79, after three successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.66%.

More news about Zai Lab.

5. Credit Acceptance Corporation (CACC) – 6.09%

Credit Acceptance Corporation provides financing programs, and related products and services to independent and franchised automobile dealers in the United States. The company advances money to dealers in exchange for the right to service the underlying consumer loans; and buys the consumer loans from the dealers and keeps various amounts collected from the consumers. It is also involved in the business of reinsuring coverage under vehicle service contracts sold to consumers by dealers on vehicles financed by the company. The company was founded in 1972 and is headquartered in Southfield, Michigan.

NASDAQ ended the session with Credit Acceptance Corporation rising 6.09% to $492.15 on Monday while NASDAQ jumped 1.48% to $11,891.79.

Earnings Per Share

As for profitability, Credit Acceptance Corporation has a trailing twelve months EPS of $40.02.

PE Ratio

Credit Acceptance Corporation has a trailing twelve months price to earnings ratio of 12.3. Meaning, the purchaser of the share is investing $12.3 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.08%.

Moving Average

Credit Acceptance Corporation’s value is above its 50-day moving average of $451.18 and below its 200-day moving average of $498.71.

Sales Growth

Credit Acceptance Corporation’s sales growth is 0.5% for the ongoing quarter and 1.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Credit Acceptance Corporation’s stock is considered to be overbought (>=80).

More news about Credit Acceptance Corporation.

6. Cloudflare (NET) – 5.84%

CloudFlare, Inc. operates as a cloud services provider that delivers a range of services to businesses worldwide. The company offers an integrated cloud-based security solution to secure a range of combination of platforms, including public cloud, private cloud, on-premise, software-as-a-service applications, and IoT devices. Its security products comprise cloud firewall, bot management, distributed denial of service, IoT, SSL/TLS, secure origin connection, and rate limiting products. The company also offers performance solutions, which include content delivery and intelligent routing, as well as content, mobile, and image optimization solutions. In addition, it provides reliability solutions comprising load balancing, anycast network, virtual backbone, DNS, DNS resolver, online, and virtual waiting room solutions. Further, the company offers Cloudflare internal infrastructure solutions, including on-ramps, which connect users, devices, or locations to its network; and filters, which are the products that protect, inspect, and privilege data. Additionally, it provides developer-based solutions, such as serverless computing/programmable network, website development, domain registration, Cloudflare apps, analytics, and data localization management; Consumer DNS Resolver, a consumer app to browse the Internet; and Consumer VPN for consumers to secure and accelerate traffic on mobile devices. The company serves customers in the technology, healthcare, financial services, consumer and retail, and non-profit industries, as well as government. CloudFlare, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NYSE ended the session with Cloudflare rising 5.84% to $63.61 on Monday while NYSE jumped 0.77% to $16,032.43.

Earnings Per Share

As for profitability, Cloudflare has a trailing twelve months EPS of $-0.7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.97%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 53.7%, now sitting on 656.43M for the twelve trailing months.

Yearly Top and Bottom Value

Cloudflare’s stock is valued at $63.61 at 16:32 EST, way under its 52-week high of $221.64 and way above its 52-week low of $45.78.

More news about Cloudflare.

7. Baidu (BIDU) – 5.55%

Baidu, Inc. offers internet search services in China. It operates through Baidu Core and iQIYI segments. The company offers Baidu App to access search, feed, and other services using mobile devices; Baidu Search to access its search and other services; Baidu Feed that provides users with personalized timeline based on their demographics and interests; and Haokan, a short video app. It also provides Baidu Knows, an online community where users can ask questions to other users; Baidu Wiki; Baidu Healthcare Wiki; Baidu Wenku; Baidu Scholar; Baidu Experience; Baidu Post; Baidu Maps, a voice-enabled mobile app that provides travel-related services; Baidu Drive; Baijiahao; and DuerOS, a smart assistant platform. In addition, it offers online marketing services, which include pay for performance, an auction-based services that allow customers to bid for priority placement of paid sponsored links and reach users who search for information related to their products or services; other marketing services that include display-based marketing services and other online marketing services based on performance criteria other than cost per click; mobile ecosystem, a portfolio of apps, including Baidu App, Haokan, and Baidu Post; various cloud services and solutions, such as platform as a service, software as a service, and infrastructure as a service; self-driving services, including maps, automated valet parking, autonomous navigation pilot, electric vehicles, and robotaxi fleets, as well as Xiaodu smart devices. Further, the company provides iQIYI, AN online entertainment service, including original and licensed content; other video content and membership; and online advertising services. Baidu, Inc. has strategic partnership with Zhejiang Geely Holding Group. The company was formerly known as Baidu.com, Inc. Baidu, Inc. was incorporated in 2000 and is headquartered in Beijing, China.

NASDAQ ended the session with Baidu jumping 5.55% to $146.71 on Monday while NASDAQ jumped 1.48% to $11,891.79.

Earnings Per Share

As for profitability, Baidu has a trailing twelve months EPS of $10.03.

PE Ratio

Baidu has a trailing twelve months price to earnings ratio of 14.62. Meaning, the purchaser of the share is investing $14.62 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.53%.

More news about Baidu.

8. Banco Bradesco (BBD) – 5.1%

Banco Bradesco S.A., together with its subsidiaries, provides various banking products and services to individuals, corporates, and businesses in Brazil and internationally. The company operates through two segments, Banking and Insurance. It provides current, savings, click, and salary accounts; real estate credit, vehicle financing, payroll loans, mortgage loans, microcredit, leasing, and personal and installment credit; debit and business cards; financial and security services; consortium products; auto, personal accident, dental, travel, and life insurance; investment products; pension products; real estate and vehicle auctions; cash management, and foreign trade and exchange services; capitalization bonds; and internet banking services. Banco Bradesco S.A. was founded in 1943 and is headquartered in Osasco, Brazil. Banco Bradesco S.A. is a subsidiary of Cidade de Deus – Companhia Comercial de Participações.

NYSE ended the session with Banco Bradesco rising 5.1% to $2.58 on Monday, after two sequential sessions in a row of losses. NYSE jumped 0.77% to $16,032.43, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Banco Bradesco has a trailing twelve months EPS of $0.299.

PE Ratio

Banco Bradesco has a trailing twelve months price to earnings ratio of 8.61. Meaning, the purchaser of the share is investing $8.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.4%.

Sales Growth

Banco Bradesco’s sales growth is 11.8% for the current quarter and negative 5.7% for the next.

Moving Average

Banco Bradesco’s value is below its 50-day moving average of $2.83 and way under its 200-day moving average of $3.50.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 95.88B for the twelve trailing months.

More news about Banco Bradesco.

9. Banco Bradesco (BBD) – 5.1%

Banco Bradesco S.A., together with its subsidiaries, provides various banking products and services to individuals, corporates, and businesses in Brazil and internationally. The company operates through two segments, Banking and Insurance. It provides current, savings, click, and salary accounts; real estate credit, vehicle financing, payroll loans, mortgage loans, microcredit, leasing, and personal and installment credit; debit and business cards; financial and security services; consortium products; auto, personal accident, dental, travel, and life insurance; investment products; pension products; real estate and vehicle auctions; cash management, and foreign trade and exchange services; capitalization bonds; and internet banking services. Banco Bradesco S.A. was founded in 1943 and is headquartered in Osasco, Brazil. Banco Bradesco S.A. is a subsidiary of Cidade de Deus – Companhia Comercial de Participações.

NYSE ended the session with Banco Bradesco rising 5.1% to $2.58 on Monday while NYSE jumped 0.77% to $16,032.43.

Earnings Per Share

As for profitability, Banco Bradesco has a trailing twelve months EPS of $0.299.

PE Ratio

Banco Bradesco has a trailing twelve months price to earnings ratio of 8.61. Meaning, the purchaser of the share is investing $8.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.4%.

More news about Banco Bradesco.

10. Momo (MOMO) – 4.94%

Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. It operates Momo platform that includes its Momo mobile application, as well as various related properties, features, functionalities, tools, and services. The company's Momo mobile application connects people and facilitates interactions based on location and interests; and various recreational activities, including live talent shows, short videos, and social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke, and user participated reality shows. It also operates Tantan, a social and dating application, which enables users to find and establish romantic connections, and meet interesting people; and provides live video, quick chat, value-added, mobile marketing, and other services, as well as mobile games and audio chatrooms. In addition, it allows its platform's users to livestream a variety of content and activities that comprise talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Momo rising 4.94% to $10.41 on Monday, after three sequential sessions in a row of losses. NASDAQ jumped 1.48% to $11,891.79, after three successive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Momo has a trailing twelve months EPS of $1.49.

PE Ratio

Momo has a trailing twelve months price to earnings ratio of 6.98. Meaning, the purchaser of the share is investing $6.98 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.23%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Momo’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.3%, now sitting on 13.69B for the twelve trailing months.

More news about Momo.

Losers Today

1. Sorrento Therapeutics (SRNE) – -73.61%

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

NASDAQ ended the session with Sorrento Therapeutics falling 73.61% to $0.25 on Monday, following the last session’s upward trend. NASDAQ rose 1.48% to $11,891.79, after three successive sessions in a row of losses, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of $-1.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -326.72%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.2%, now sitting on 54.98M for the twelve trailing months.

More news about Sorrento Therapeutics.

2. Fidelity National Information Services (FIS) – -12.61%

Fidelity National Information Services, Inc. provides technology solutions for merchants, banks, and capital markets firms worldwide. It operates through Merchant Solutions, Banking Solutions, and Capital Market Solutions segments. The Merchant Solutions segment offers enterprise acquiring, software-led small- to medium-sized businesses acquiring, and global e-commerce solutions. The Banking Solutions segment provides core processing and ancillary applications; digital solutions, including Internet, mobile, and e-banking; fraud, risk management, and compliance solutions; electronic funds transfer and network services; card and retail payment solutions; wealth and retirement solutions; and item processing and output services. The Capital Market Solutions segment offers securities processing and finance, global trading, asset management and insurance, and corporate liquidity solutions. Fidelity National Information Services, Inc. was founded in 1968 and is headquartered in Jacksonville, Florida.

NYSE ended the session with Fidelity National Information Services dropping 12.61% to $65.92 on Monday, after four sequential sessions in a row of gains. NYSE jumped 0.77% to $16,032.43, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Fidelity National Information Services has a trailing twelve months EPS of $0.25.

PE Ratio

Fidelity National Information Services has a trailing twelve months price to earnings ratio of 263.68. Meaning, the purchaser of the share is investing $263.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.79%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Fidelity National Information Services’s stock is considered to be oversold (<=20).

Volatility

Fidelity National Information Services’s last week, last month’s, and last quarter’s current intraday variation average was 0.82%, 0.61%, and 1.62%.

Fidelity National Information Services’s highest amplitude of average volatility was 1.45% (last week), 1.32% (last month), and 1.62% (last quarter).

Moving Average

Fidelity National Information Services’s value is below its 50-day moving average of $69.09 and way under its 200-day moving average of $85.79.

More news about Fidelity National Information Services.

3. Blink Charging Co. (BLNKW) – -8.05%

NASDAQ ended the session with Blink Charging Co. sliding 8.05% to $6.00 on Monday, after five consecutive sessions in a row of losses. NASDAQ rose 1.48% to $11,891.79, after three sequential sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Yearly Top and Bottom Value

Blink Charging Co.’s stock is valued at $6.00 at 16:32 EST, way under its 52-week high of $6.74 and above its 52-week low of $5.90.

More news about Blink Charging Co..

4. Baudax Bio (BXRX) – -6.52%

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

NASDAQ ended the session with Baudax Bio sliding 6.52% to $2.62 on Monday, after three consecutive sessions in a row of losses. NASDAQ rose 1.48% to $11,891.79, after three sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Baudax Bio has a trailing twelve months EPS of $250.96.

PE Ratio

Baudax Bio has a trailing twelve months price to earnings ratio of 0.01. Meaning, the purchaser of the share is investing $0.01 for every dollar of annual earnings.

More news about Baudax Bio.

5. Blink Charging Co. (BLNK) – -5.35%

Blink Charging Co., through its subsidiaries, owns, operates, and provides electric vehicle (EV) charging equipment and networked EV charging services in the United States. The company offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. It also provides Blink Network, a cloud-based system that operates, maintains, and tracks various Blink charging stations and associated charging data, back-end operations, and payment processing, as well as provides property owners, managers, parking companies, and state and municipal entities with cloud-based services that enable the remote monitoring and management of EV charging stations; and provides EV drivers with station information, including station location, availability, and applicable fees. In addition, the company provides EV charging hardware, software services, and service plans. It has strategic partnerships across transit/destination locations, including airports, auto dealers, healthcare/medicals, hotels, mixed-use, municipal locations, multifamily residential and condos, parks and recreation areas, parking lots, religious institutions, restaurants, retailers, schools and universities, stadiums, supermarkets, transportation hubs, and workplace locations. The company offers its services through field sales force and resellers, as well as sells residential Level 2 chargers through various internet channels. As of December 31, 2020, it deployed approximately 16,617 EV charging stations. Blink Charging Co. was founded in 2009 and is headquartered in Miami Beach, Florida.

NASDAQ ended the session with Blink Charging Co. sliding 5.35% to $10.26 on Monday while NASDAQ jumped 1.48% to $11,891.79.

Earnings Per Share

As for profitability, Blink Charging Co. has a trailing twelve months EPS of $-0.59.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.37%.

Yearly Top and Bottom Value

Blink Charging Co.’s stock is valued at $10.26 at 16:32 EST, way below its 52-week high of $29.99 and above its 52-week low of $9.85.

More news about Blink Charging Co..

6. Celcuity (CELC) – -5.19%

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with Celcuity dropping 5.19% to $11.14 on Monday, after five consecutive sessions in a row of gains. NASDAQ jumped 1.48% to $11,891.79, after three sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Celcuity has a trailing twelve months EPS of $-0.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.48%.

Moving Average

Celcuity’s worth is above its 50-day moving average of $10.86 and way higher than its 200-day moving average of $9.37.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 41.5% and positive 2.2% for the next.

More news about Celcuity.

7. BeyondSpring (BYSI) – -5.08%

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

NASDAQ ended the session with BeyondSpring sliding 5.08% to $2.12 on Monday, after four successive sessions in a row of losses. NASDAQ rose 1.48% to $11,891.79, after three consecutive sessions in a row of losses, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, BeyondSpring has a trailing twelve months EPS of $-1.645.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -115.41%.

Sales Growth

BeyondSpring’s sales growth is 0.6% for the present quarter and 0.6% for the next.

More news about BeyondSpring.

8. AMC (AMC) – -4.39%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC dropping 4.39% to $4.69 on Monday, after five successive sessions in a row of losses. NYSE rose 0.77% to $16,032.43, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-39.152.

Revenue Growth

Year-on-year quarterly revenue growth grew by 162.3%, now sitting on 3.89B for the twelve trailing months.

More news about AMC.

9. Xenetic Biosciences (XBIO) – -4.03%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences sliding 4.03% to $0.58 on Monday, after four sequential sessions in a row of losses. NASDAQ rose 1.48% to $11,891.79, after three successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.34%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 44.9%, now sitting on 1.49M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).

Moving Average

Xenetic Biosciences’s worth is way higher than its 50-day moving average of $0.40 and below its 200-day moving average of $0.64.

Sales Growth

Xenetic Biosciences’s sales growth for the next quarter is negative 27.9%.

More news about Xenetic Biosciences.

10. Burning Rock Biotech Limited (BNR) – -3.53%

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.

NASDAQ ended the session with Burning Rock Biotech Limited sliding 3.53% to $3.01 on Monday while NASDAQ jumped 1.48% to $11,891.79.

Earnings Per Share

As for profitability, Burning Rock Biotech Limited has a trailing twelve months EPS of $-1.059.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.42%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 26.9% and positive 16.7% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.8%, now sitting on 540.33M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Burning Rock Biotech Limited’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for Burning Rock Biotech Limited is 197277 which is 10.96% below its average volume of 221568.

More news about Burning Rock Biotech Limited.

Stay up to date with our winners and losers daily report